These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 6495457)
1. Ifosfamide: chemotherapy with new promise and new problems for the urologist. Watson RA Urology; 1984 Nov; 24(5):465-8. PubMed ID: 6495457 [TBL] [Abstract][Full Text] [Related]
2. Ifosfamide and mesna. Med Lett Drugs Ther; 1989 Nov; 31(804):98-9. PubMed ID: 2554100 [No Abstract] [Full Text] [Related]
3. Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation. Fujita J; Matsumoto K; Kakizoe T; Murase T Urology; 1981 Sep; 18(3):250-1. PubMed ID: 7281389 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria. Slavik M; Saiers JH Semin Oncol; 1983 Mar; 10(1 Suppl 1):62-5. PubMed ID: 6836328 [No Abstract] [Full Text] [Related]
5. [Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide]. Brühl P; Hoefer-Janker H; Scheef W; Vahlensieck W Onkologie; 1979 Jun; 2(3):120-4. PubMed ID: 42866 [TBL] [Abstract][Full Text] [Related]
6. Nursing implications in the administration of ifosfamide and mesna. Richters JE Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534 [No Abstract] [Full Text] [Related]
7. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)]. Hoefer H; Scheef W; Titscher R; Kokron O Osterr Z Onkol; 1974; (1):3-7. PubMed ID: 4619650 [No Abstract] [Full Text] [Related]
9. N-acetylcysteine in the prevention of cyclophosphamide induced haemorrhagic cystitis. Palma PC; Villaça Júnior CJ; Netto Júnior NR Int Surg; 1986; 71(1):36-7. PubMed ID: 3522468 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. Schnitker J; Brock N; Burkert H; Fichtner E Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586 [TBL] [Abstract][Full Text] [Related]
11. N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer. Loehrer PJ; Williams SD; Einhorn LH Semin Oncol; 1983 Mar; 10(1 Suppl 1):72-5. PubMed ID: 6836331 [No Abstract] [Full Text] [Related]
12. [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna]. Matsumoto S; Kawaguchi N; Manabe J; Kuroda H; Shimoji T Gan To Kagaku Ryoho; 1995 Jun; 22(7):965-8. PubMed ID: 7794006 [No Abstract] [Full Text] [Related]
13. Ifosfamide vs cyclophosphamide in cancer therapy. Weiss RB Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004 [TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan]. Czownicki Z; Utracka-Hutka B Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599 [No Abstract] [Full Text] [Related]
15. Use and safety of high-dose ifosfamide. Holoye PY; Anderson T; Duelge J; Hansen RM; Ritch PS Semin Oncol; 1982 Dec; 9(4 Suppl 1):78-86. PubMed ID: 6298946 [No Abstract] [Full Text] [Related]
16. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585 [TBL] [Abstract][Full Text] [Related]